comprehensive -WSS

comprehensive

author：hotspot 2025-09-01 15:16:18 - browse：67

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： The struggle to figure out which patients 'deserve' Wegovy

WSS

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

White House drug czar issues call for 'recovery

Cancer diagnosis changes perspective doctor, former hospital CEO

Study suggests Covid rebound is far more common with Paxlovid than without

Ohio still needs to do more to protect the right to abortion

Transgender sports debate: Physicians say bans are health issue

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Hollywood unions extend contract negotiations for actors

Healthy food access boosts outcomes in two studies

Medical leaders decry Supreme Court decision on affirmative action

Weight loss drugs should be covered by insurers, AMA says

Bright Health sells Medicare Advantage business to Molina

Free Covid tests will again be offered to all U.S. households

In Memoriam: Notable people who died in 2023

White House Covid adviser calls on docs to combat misinformation

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

House panel takes first step toward fixing drug shortages

focus

Why the quest to eradicate polio has stumbled

Neurocrine congenital adrenal hyperplasia trial succeeds

Ventyx halts psoriasis drug development after lackluster trial results

Experimental asthma app from Apple and Anthem shows promise

FDA reorg will put new emphasis on investigations, sources say

Ventyx halts psoriasis drug development after lackluster trial results

focus

knowledge

hotspot

Wikipedia